Peripheral Neuropathy Associated With Ipilimumab: A Report of 2 Cases
Year: 2015
Type: article
Study design: Case Report
Abstract: Ipilimumab, a monoclonal antibody targeting human cytotoxic T-lymphocyte-associated antigen 4, was approved by the FDA and European Medicines Agency for the treatment of metastatic melanoma. Immune-related adverse effects can occur with the use of this agent, but peripheral nervous system problems are rare. We report 2 cases of ipilimumab-induced polyneuropathy.
Source: Journal of Immunotherapy
Institutions: Memorial Sloan Kettering Cancer Center, Neurology, Inc
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: National Cancer Institute
Award: Cancer Center Support Grant
OpenAlex ID: W2329842261
